希罗达联合多西紫杉醇治疗晚期乳腺癌40例临床观察  

Clinical Observation of Xeloda and Docetaxel for Advanced Breast Cancer

作　　者：燕平[1] 艾淑颖[1] 李志玖[1] 何清华 

机构地区：[1]湖北医药学院附属太和医院肿瘤科,442000 [2]十堰市中医院,442000

出　　处：《实用癌症杂志》2014年第3期327-329,共3页The Practical Journal of Cancer

摘　　要：目的探讨希罗达联合多西紫杉醇治疗晚期乳腺癌的疗效及不良反应。方法将40例晚期乳腺癌患者随机分为2组,联合组(n=20例)采用希罗达1 250 mg/m2,每天2次口服,连用14天。多西紫杉醇75 mg/m2,静脉滴注,第1天。对照组(n=20例)采用多西紫杉醇75 mg/m2,静脉滴入,第1天,21天为1个周期。治疗2个周期后评价疗效及不良反应。结果联合组有效率(CR+PR)为65.0%,中位生存时间为16.5个月,主要不良反应为手足综合征、骨髓抑制、脱发和消化道毒性。对照组有效率(CR+PR)为45.0%,中位生存时间为10.9个月。对照组不良反应主要为骨髓抑制、消化道毒性、发热、肌痛、关节痛等。2组有效率和生存期比较,差异均有统计学意义(P<0.05)。结论希罗达联合多西紫杉醇作为二线方案治疗晚期乳腺癌的疗效确切,优于单一多西紫杉醇治疗,且不良反应轻,可以作为紫杉类或蒽环类药物治疗失败的晚期乳腺癌的解救方案。Objective To observe the efficacy and toxicities of xeloda combined with docetaxel for advanced breast canc -er.Methods 40 patients with advanced breast cancer were randomly divided into two groups .In the combining group ,xeloda was given 1 250 mg/m2 twice a day for 14 days,and docetaxel was given 75 mg/m2 during the 1st day.In the control group ,docetaxel was given 75 mg/m2 during the 1st day.The chemotherapy was repeated every 3 weeks.Efficacy and toxicities were reviewed after 2 cycles of chemotherapy .Results In the combining group ,the effective rate was 65.0% and median survival time was 16.5 months.Most common side effects were hand-foot syndrome,myelosuppression,baldness and gastrointestinaltoxicities ,etc.In the control group,the effective rate was 45.0%and median survival time was 10.9 months.Most commont toxicities were myelosup-pression,gastrointestinal toxicities,fever,myalgiaandarthralgia etc.There was statistical difference (P<0.05).Conclusion Xe-loda combined with Docetaxel is an effective as second-line chemotherapy for advanced breast cancer .The overall survival is sig-nificantly prolonged ,toxicities are mild and acceptable .This regimen could be used for patients failed taxol and anthracycline .

关 键 词：乳腺癌 希罗达 多西紫杉醇 

分 类 号：R737.9[医药卫生—肿瘤]